Rare diseases, orphan drugs and their regulation: questions and misconceptions
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Sustained advocacy efforts driven by patients' organizations to make rare diseases a health priority have led to regulatory and economic incentives for industry to develop drugs for these diseases, known as orphan drugs. These incentives, enacted in regulations first introduced in the United States in 1983 and later in Japan, Europe and elsewhere, have resulted in substantial improvements in the treatment for patients with a range of rare diseases. However, the advent of orphan drug development has also triggered several questions, from the definition of rarity to the pricing of orphan drugs and their impact on health-care systems. This article provides an industry perspective on some of the common questions and misconceptions related to orphan drug development and its regulation, with the aim of facilitating future progress in the field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Standard randomized placebo-controlled clinical trials in hundreds of patients will therefore be difficult to achieve for ASD, and specific clinical trials designed for rare diseases need to be devised 90 .”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [90]
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“, although others claim that this number could be as high as 50”
BackgroundRelative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Eichler, H.-G., Bloechl-Daum, B., Abadie, E., Barnett, D., König, F., & Pearson, S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3079 · Cited by 174
The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
Wellman-Labadie, O., & Zhou, Y. (2010) · Health Policy · doi:10.1016/j.healthpol.2009.12.001 · Cited by 166
Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases
Haffner, M. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp058317 · Cited by 162
Orphan drug development is not taking off
Joppi, R., Bertelè, V., & Garattini, S. K. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03369.x · Cited by 64
Orphan drug policies: implications for the United States, Canada, and developing countries.
Cheung, R. Y., Cohen, J. C., & Illingworth, P. (2004) · PubMed · Cited by 49
From research on rare diseases to new orphan drug development
Heemstra, H. (2010) · Utrecht University Repository (Utrecht University) · Cited by 3
Research works printed but not linked: 5
- La Revue Prescire – Enquête. Médicaments pour les maladies rares: bilan contrasté en Europe — Synthèse élaborée collectivement par la Rédaction. La Revue Prescire 26, 781 (2006) (in French).
- Hirschhorn, R. & Reuser A. J. J. in The Metabolic & Molecular Bases of Inherited Diseases 8th edn (eds Scriver C. R. et al.) 3395 (McGraw-Hill, New York, 2001).
- Genzyme Corporation. Genzyme annual report 2004. (Genzyme, Cambridge, Massachusetts, 2004).
- The European Platform for Patients' Organisations, Science and Industry. The 8th workshop on partnering for rare disease therapy development: the reality of orphan medicines. The Platform for Patients' Organisations, Science and Industry website [ online ], (2007).
- Commission of the European Communities. Guideline on aspects of the application of Article 8(2) of Regulation (EC) No 141/2000: review of the period of market exclusivity of orphan medicinal products. The European Commission website [ online ], (2008).
Cited by
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Self-citationGammie, T., Lu, C. Y., & Babar, Z. U.-D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140002 · Cited by 277
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Pricing and reimbursement of orphan drugs: the need for more transparency
Simoens, S. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-42 · Cited by 260
Drug repositioning for personalized medicine
Li, Y. Y., & Jones, S. J. (2012) · Genome Medicine · doi:10.1186/gm326 · Cited by 248
Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective
Austin, C. P., Cutillo, C. M., Lau, L. P. L., Jonker, A. H., Rath, A., Julkowska, D., Thomson, D., Terry, S. F., de Montleau, B., Ardigò, D., et al. (2018) · Clinical and Translational Science · doi:10.1111/cts.12500 · Cited by 241
Progress toward treatments for synaptic defects in autism
Delorme, R., Ey, E., Toro, R., Leboyer, M., Gillberg, C., & Bourgeron, T. (2013) · Nature Medicine · doi:10.1038/nm.3193 · Cited by 218
Rare diseases and orphan drugs
Melnikova, I. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3654 · Cited by 213
Progress in Rare Diseases Research 2010–2016: An IRDiRC Perspective
Dawkins, H. J. S., Draghia‐Akli, R., Lasko, P., Lau, L. P. L., Jonker, A. H., Cutillo, C. M., Rath, A., Boycott, K. M., Baynam, G., Lochmüller, H., et al. (2018) · Clinical and Translational Science · doi:10.1111/cts.12501 · Cited by 178
Orphan drug development: an economically viable strategy for biopharma R&D
Meekings, K. N., Williams, C. S. M., & Arrowsmith, J. E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.005 · Cited by 160
Orphan drugs: the regulatory environment
Franco, P. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.08.009 · Cited by 144
Old friends in new guise: repositioning of known drugs with structural bioinformatics
Haupt, V. J., & Schroeder, M. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr011 · Cited by 153
Bell, S., & Smith, C. T. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0170-0 · Cited by 145
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Schey, C., Milanova, T. F., & Hutchings, A. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-62 · Cited by 133
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Jayasundara, K., Hollis, A., Krahn, M., Mamdani, M., Hoch, J. S., & Grootendorst, P. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0990-4 · Cited by 127
Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives
Song, P. (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.1.3 · Cited by 117
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis
Rees, C. A., Pica, N., Monuteaux, M. C., & Bourgeois, F. T. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002966 · Cited by 111
Allarakhia, M. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46289 · Cited by 116
Drug-target interaction prediction: A Bayesian ranking approach
Peška, L., Búza, K., & Koller, J. (2017) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2017.09.003 · Cited by 95
Wagner, M., Khoury, H., Willet, J., Rindress, D., & Goetghebeur, M. M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0340-5 · Cited by 84
Orphan Drugs for Rare Diseases: Is it Time to Revisit Their Special Market Access Status?
Simoens, S., Cassiman, D. M., Dooms, M. M., & Picavet, E. (2012) · Drugs · doi:10.2165/11635320-000000000-00000 · Cited by 95
Schlander, M., Garattini, S. K., Holm, S., Kolominsky‐Rabas, P. L., Nord, E., Persson, U., Postma, M. J., Richardson, J. R. J., Simoens, S., Morales, O. D. S., et al. (2014) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.14.34 · Cited by 87
Giannuzzi, V., Conte, R., Landi, A., Ottomano, S. A., Bonifazi, D., Baiardi, P., Bonifazi, F., & Ceci, A. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0617-1 · Cited by 71
Zelei, T., Molnár, M. J., Szegedi, M., & Kaló, Z. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0455-6 · Cited by 67
Hughes, D. A., & Poletti‐Hughes, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164681 · Cited by 76
Orphan drugs: major development challenges at the clinical stage
Fonseca, D. A., Amaral, I., Pinto, A. C. R., & Cotrim, M. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.005 · Cited by 66
Clinical applications of gene therapy for rare diseases: A review
Papaioannou, I., Owen, J. S., & Yáñez‐Muñoz, R. J. (2023) · International Journal of Experimental Pathology · doi:10.1111/iep.12478 · Cited by 79
Song, C. H., & Han, J. (2016) · SpringerPlus · doi:10.1186/s40064-016-2323-1 · Cited by 74
Evolution of drug regulations and regulatory innovation for anticancer drugs in China
Liu, Y., Zhang, N., Xie, C., Jiang, Y., Qin, Y., Zhou, L., Fan, Y., Ren, L., Yin, C., Yang, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.004 · Cited by 61
Investigating the landscape of US orphan product approvals
Miller, K. L., & Lanthier, M. L. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0930-3 · Cited by 62
Rare lung disease and orphan drug development
Spagnolo, P., du Bois, R. M., & Cottin, V. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70085-7 · Cited by 52
What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis
Thorat, C., Xu, K., Freeman, S. N., Bonnel, R. A., Joseph, F. D., Phillips, M. I., & Imoisili, M. A. (2012) · PEDIATRICS · doi:10.1542/peds.2011-1798 · Cited by 47
Sustainable rare diseases business and drug access: no time for misconceptions
Rollet, P., Lemoine, A., & Dunoyer, M. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-109 · Cited by 48
Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing
Madugula, S. S., John, L., Nagamani, S., Gaur, A. S., Poroikov, V., & Sastry, G. N. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104856 · Cited by 48
Tingley, K., Coyle, D., Graham, I. D., Chakraborty, P. K., Wilson, K. R., & Potter, B. K. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01624-0 · Cited by 44
Orphan/rare drug discovery through drug repositioning
Muthyala, R. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.003 · Cited by 62
Rare diseases and orphan drugs.
Taruscio, D., Capozzoli, F., & Frank, C. (2011) · PubMed · doi:10.4415/ann_11_01_17 · Cited by 38
de Oliveira, E. A. M., & Lang, K. L. (2018) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2018.8822 · Cited by 50
Michaeli, D. T., Mills, M. J., Michaeli, T., Miracolo, A., & Kanavos, P. G. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01227-5 · Cited by 38
Enzyme Replacement Therapy for Genetic Disorders Associated with Enzyme Deficiency
Marchetti, M., Faggiano, S., & Mozzarelli, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210526144654 · Cited by 42
A systematic review of moral reasons on orphan drug reimbursement
Zimmermann, B. M., Eichinger, J., & Baumgartner, M. R. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01925-y · Cited by 47
Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children
Balevic, S. J., & Cohen‐Wolkowiez, M. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1053 · Cited by 38
Widespread genome transcription: New possibilities for RNA therapies
Takahashi, H., & Carninci, P. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.139 · Cited by 35
Clinical evidence for orphan medicinal products-a cause for concern?
Picavet, E., Cassiman, D. M., Hollak, C. E. M., Maertens, J. A., & Simoens, S. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-164 · Cited by 35
Determinants for successful marketing authorisation of orphan medicinal products in the EU
Putzeist, M., Heemstra, H. E., Llinares, J., Mantel-Teeuwisse, A. K., Wied, C. C. G., Hoes, A. W., & Leufkens, H. G. M. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.027 · Cited by 34
Principles for consistent value assessment and sustainable funding of orphan drugs in Europe
Gutierrez, L., Patris, J., Hutchings, A., & Cowell, W. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0269-y · Cited by 33
Franco, P., Porta, N., Holliday, J. D., & Willett, P. (2014) · Journal of Cheminformatics · doi:10.1186/1758-2946-6-5 · Cited by 31
In Silico Drug Design Methods for Drug Repurposing
Akhoon, B. A., Tiwari, H., & Nargotra, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00003-1 · Cited by 37
Chen, B., & Altman, R. B. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0614-4 · Cited by 28
“Background Rare diseases are defined as diseases affecting fewer than 200,000 patients in the US or fewer than 1 in 2000 people in the EU; over 25 million Americans suffer from at least one of 7000 rare diseases [1].”
BackgroundClinical pharmacology as a cornerstone of orphan drug development
Bashaw, E. D., Huang, S. M., Coté, T. R., Pariser, A., Garnett, C. E., Burckart, G. J., Zhang, L., Men, A. Y., Le, C. D., Charlab, R., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3595 · Cited by 27
Liposomal formulations for treating lysosomal storage disorders
Tomsen-Melero, J., Merlo‐Mas, J., Carreño, A., Sala, S., Córdoba, A., Veciana, J., González‐Mira, E., & Ventosa, N. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114531 · Cited by 27
Orphan Drugs for Rare Diseases: Grounds for Special Status
Picavet, E., Dooms, M. M., Cassiman, D. M., & Simoens, S. (2012) · Drug Development Research · doi:10.1002/ddr.21005 · Cited by 26
Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering—A Cross-Sectional Analysis
Stockklausner, C., Lampert, A., Hoffmann, G. F., & Ries, M. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0397 · Cited by 26
Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements
Mincarone, P., Leo, C. G., Sabina, S., Sarría‐Santamera, A., Taruscio, D., Serrano‐Aguilar, P., & Kanavos, P. G. (2017) · Public Health Genomics · doi:10.1159/000464100 · Cited by 28
Goetghebeur, M. M., Wagner, M., Samaha, D., O’Neil, W. M., Badgley, D., Castro-Jaramillo, H., Abrishami, P., Sarría‐Santamera, A., Cleemput, I., & Tringali, M. (2017) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462317000915 · Cited by 27
Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
Picavet, E., Cassiman, D. M., & Simoens, S. (2012) · Health Policy · doi:10.1016/j.healthpol.2012.08.023 · Cited by 25
Rosselli, D., Rueda, J. D., & Solano, M. L. (2012) · Journal of Medical Ethics · doi:10.1136/medethics-2011-100204 · Cited by 25
Experience With Pediatric Medical Device Development
Humes, H. D., & Westover, A. J. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.00079 · Cited by 22
Horgan, D., Moss, B., Boccia, S., Genuardi, M., Gajewski, M., Capurso, G., Fenaux, P., Gulbis, B., Pellegrini, M., Pereira, M. D. M. M., et al. (2020) · Biomedicine Hub · doi:10.1159/000509272 · Cited by 21
Cui, Y., & Han, J. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0241-x · Cited by 20
Simoens, S., & Huys, I. (2017) · Gene Therapy · doi:10.1038/gt.2017.79 · Cited by 20
Geographic and Specialty Access Disparities in US Pediatric Leukodystrophy Diagnosis
Grineski, S. E., Morales, D. X., Collins, T. W., Wilkes, J., & Bonkowsky, J. L. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.01.063 · Cited by 21
Uncovering novel repositioning opportunities using the Open Targets platform
Khaladkar, M., Koscielny, G., Hasan, S., Agarwal, P., Dunham, I., Rajpal, D. K., & Sanséau, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.007 · Cited by 18
Saviano, M., Barile, S., Caputo, F., Lettieri, M., & Zanda, S. (2019) · Sustainability · doi:10.3390/su11051289 · Cited by 24
Intractable and rare diseases research
Tang, N. L. S. (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.1.1 · Cited by 19
Petersen, K. E., Prows, C. A., Martin, L. J., & Maglo, K. N. (2014) · Public Health Genomics · doi:10.1159/000362359 · Cited by 26
Vidal, A. V., Reed, S., & Schulman, K. A. (2012) · Health Affairs · doi:10.1377/hlthaff.2012.0235 · Cited by 18
Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe
Schlander, M., Adarkwah, C. C., & Gandjour, A. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.965156 · Cited by 22
A systematic review of research into rare diseases in the educational sphere
Urrutxı, L. D., Gaintza, Z., & Javier, M.-G. (2017) · Educational Research and Reviews · doi:10.5897/err2017.3186 · Cited by 18
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Brabers, A. E., Moors, E. H. M., van Weely, S., & de Vrueh, R. L. A. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-59 · Cited by 15
EU marketing authorization review of orphan and non-orphan drugs does not differ
Putzeist, M., Mantel-Teeuwisse, A. K., Llinares, J., Wied, C. C. G., Hoes, A. W., & Leufkens, H. G. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.012 · Cited by 18
Paolo, A. D., & Arrigoni, E. (2018) · Drugs · doi:10.1007/s40265-018-0882-x · Cited by 16
Orphan drug designation – Europe, the USA and Japan
O’Connor, D. J. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.769876 · Cited by 15
Do ultra-orphan medicinal products warrant ultra-high prices? A review
Picavet, E., Cassiman, D. M., & Simoens, S. (2013) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s33085 · Cited by 14
The impact of The Rare Disease and Orphan Drug Act in Taiwan
Hsiang, N.-C., Huang, W., Gau, C., Tsai, T.-W., & Chang, L. (2021) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3383 · Cited by 17
Rare Diseases in the Educational Field: Knowledge and Perceptions of Spanish Teachers
Perales, R. G., Ruíz, A. P., Ordóñez-García, L., & García-Toledano, E. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19106057 · Cited by 21
When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing
Balderrama, F., Schwartz, L. J., & Longo, C. J. (2020) · Health Care Analysis · doi:10.1007/s10728-020-00394-x · Cited by 13
Schuller, Y., Hollak, C. E. M., Wied, C. C. G., Stoyanova-Beninska, V. V., & Biegstraaten, M. (2017) · Drugs · doi:10.1007/s40265-017-0788-z · Cited by 16
Florio, M., & Gamba, S. (2021) · Annals of Public and Cooperative Economics · doi:10.1111/apce.12341 · Cited by 13
Background Paper 6.19 Rare Diseases
Baekelandt, E. R. F. (2013) · Cited by 12
Health disparities: Exploring the ethics of orphan drugs
Kinney, J. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130348 · Cited by 11
R&D and market size: Who benefits from orphan drug legislation?
Gamba, S., Magazzini, L., & Pertile, P. (2021) · Journal of Health Economics · doi:10.1016/j.jhealeco.2021.102522 · Cited by 12
Raspa, M., Moultrie, R., Wagner, L., Edwards, A., Andrews, S. M., Frisch, M., Turner‐Brown, L., & Wheeler, A. (2020) · Journal of Medical Internet Research · doi:10.2196/16734 · Cited by 13
Song (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.2.95 · Cited by 10
Recent Advances in Biotherapeutics Drug Discovery and Development
Zhong, X., Neumann, P. J., Corbo, M., & Loh, E. (2011) · InTech eBooks · doi:10.5772/28094 · Cited by 11
Mizoguchi, H., Yamanaka, T., & Kano, S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.014 · Cited by 12
Pauwels, K., Huys, I., Casteels, M., Larsson, K., Voltz-Girolt, C., Penttilä, K., Morel, T., & Simoens, S. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0578-4 · Cited by 9
Oo, C., & Rusch, L. M. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.599 · Cited by 9
Vlaar, A. P. J., van Son, W. J., & Bakker, W. W. (2008) · Nephron Physiology · doi:10.1159/000183178 · Cited by 9
Retrospective outcomes studies for orphan diseases: challenges and opportunities
Sun, P., & Garrison, L. P. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.673480 · Cited by 9
Dane, A., Groot, C. U.-D., & van der Kuy, P. H. M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1298923 · Cited by 10
Physician-patient relationship in rare diseases: an ethical approach
Hanganu, B., Manoilescu, I. S., Bîrlescu, A. E., Mocanu, V., Hleșcu, A. A., & Ioan, B. G. (2019) · Archives of the Balkan Medical Union · doi:10.31688/abmu.2019.54.1.23 · Cited by 8
Clinical Trials in Autosomal Dominant Polycystic Kidney Disease
Yu, A. S. L., Ters, M. E., & Winklhofer, F. T. (2015) · Codon Publications eBooks · doi:10.15586/codon.pkd.2015.ch6 · Cited by 10
Qosa, H., Hassan, H. E., & Younis, I. R. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2167 · Cited by 8
Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement
Lalhmangaihzuala, S., Vanlaldinpuia, K., Khiangte, V., Laldinpuii, Z., liana, T., Lalhriatpuia, C., & Pachuau, Z. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10810-2 · Cited by 15
Paces of Costly Care: Rare Disease Drug Access in Canada
McGuire, M. (2019) · Medical Anthropology · doi:10.1080/01459740.2019.1573229 · Cited by 8
Making Sure That Orphan Incentives Tip the Right Way in Europe
Horgan, D., Koeva-Balabanova, J., Capoluongo, E., Jagielska, B., Cattaneo, I., Kozaric, M., Tumiene, B., Ahl, J.-P. E., Lal, J. A., Kalra, D., et al. (2022) · Healthcare · doi:10.3390/healthcare10091600 · Cited by 10
Dane, A., Gebbink, A.-S. K., Brugma, J.-D. C., Degrassat-Théas, A., Hug, M. J., Houlind, M. B., Paubel, P., van der Kuy, P. H. M., & Groot, C. A. U. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00832-6 · Cited by 7
Definitions, History and Regulatory Framework for Rare Diseases and Orphan Drugs
Pryde, D. C., & Groft, S. C. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00003 · Cited by 7
Metadata
- Authors
- Tambuyzer, E.
- Corresponding author
- Tambuyzer, Erik
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-11-09
- Volume
- 9
- Issue
- 12
- Pages
- 921-929
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2019375534
- Cited by
- 182
- References
- 7
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 13 · 2021: 16 · 2020: 7 · 2019: 11 · 2018: 6 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 15 · 2013: 15 · 2012: 17
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- rare diseases, orphan drugs, orphan drug regulation, regulatory incentives, drug pricing, health care system impact, patient advocacy, pharmaceutical industry perspective
- MeSH terms
- Humans, Orphan Drug Production, United States, United States Food and Drug Administration, Drug Approval, Rare Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.